-
1 Comment
Kaken Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Kaken Pharmaceutical Co., Ltd's total revenue sank by 18.9% to $20B since the same quarter in the previous year.
Its net income has dropped by 38.3% to $4B since the same quarter in the previous year.
Based on the above factors, Kaken Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | JP3207000005 |
| Market Cap | 143B |
|---|---|
| PE Ratio | 10.17 |
| Dividend Yield | 5.1% |
| Target Price | 4850 |
| Beta | 0.04 |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective next-generation oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4521.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
